Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PDE4A | P27815 | 2/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111685 | 0.84 | PKM (0.39) | ALDH1A1PDE4APDE4CPDE4DKMT2A | |
| SCHEMBL1598389 | 0.79 | KMT2A (0.50) | ALDH1A1PDE4APDE4CPDE4DKMT2A | |
| SCHEMBL20985696 | 0.78 | ALDH1A1 (0.36) | ALDH1A1PDE4APDE4CPDE4DKMT2A | |
| SCHEMBL8275393 | 0.77 | HTR1D (0.33) | ALDH1A1 | |
| SCHEMBL13707280 | 0.74 | ALDH1A1 (0.36) | ALDH1A1PDE4APDE4CPDE4DKMT2A | |
| SCHEMBL1271969 | 0.71 | ALDH1A1 (0.37) | ALDH1A1KMT2AMEN1THRBPOLB | |
| SCHEMBL1272010 | 0.71 | POLB (0.42) | ALDH1A1KMT2AMEN1HTTPOLB | |
| SCHEMBL3950317 | 0.66 | P2RY12 (0.49) | ALDH1A1KMT2AMEN1POLB | |
| SCHEMBL14458076 | 0.64 | LMNA (0.42) | ALDH1A1PDE4APDE4CPDE4DKMT2A | |
| SCHEMBL1314787 | 0.64 | PDE4A (0.41) | PDE4APDE4CPDE4DKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379530-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ASTRAZENECA (SE) | 2011-03-03 | — | — | US | disclosed |
| WO-2010073034-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ABCG2, CYP3A7, CYP2C19 | ALDH1A1 112/4885PDE4A 1181/4885PDE4C 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.